-
EP4081639
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4081639
| EP4081639 - PHARMACEUTICAL COMBINATION OF A THERAPEUTIC OLIGONUCLEOTIDE TARGETING HBV AND A TLR7 AGONIST FOR TREATMENT OF HBV [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 30.09.2022 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 07.07.2021 | ||
| Former | unknown Status updated on 02.02.2021 | Most recent event Tooltip | 19.12.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2022/44] | Inventor(s) | 01 /
GAO, Lu c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720 Cailun Road Shanghai 201203 / CN | 02 /
ZHU, Yonghong c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720 Cailun Road Shanghai 201203 / CN | 03 /
OTTOSEN, Søren c/o Roche Innovation Center Copenhagen A/S Fremtidsvej 3 2970 Hørsholm / DK | 04 /
MUELLER, Henrik c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 05 /
ZHOU, Xue c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720 Cailun Road Shanghai 201203 / CN | 06 /
BLAISING, Julie Elisabeth Françoise c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 07 /
JIN, Yuyan c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720 Cailun Road Shanghai 201203 / CN | 08 /
BO, Qingyan c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720 Cailun Road Shanghai 201203 / CN | 09 /
TYAGI, Gaurav c/o Roche TCRC, Inc. East 29th Street Alexandria Center for Life Science New York, NY 10016 / US | [2022/44] | Representative(s) | D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [N/P] |
| Former [2022/44] | D Young & Co LLP 120 Holborn London EC1N 2DY / GB | Application number, filing date | 20845154.2 | 22.12.2020 | [2022/44] | WO2020EP87697 | Priority number, date | WO2019CN127972 | 24.12.2019 Original published format: PCT/CN2019/127972 | WO2020CN107002 | 05.08.2020 Original published format: PCT/CN2020/107002 | [2022/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021130266 | Date: | 01.07.2021 | Language: | EN | [2021/26] | Type: | A1 Application with search report | No.: | EP4081639 | Date: | 02.11.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 01.07.2021 takes the place of the publication of the European patent application. | [2022/44] | Search report(s) | International search report - published on: | EP | 01.07.2021 | Classification | IPC: | C12N15/113, A61K31/4375, A61K31/506, A61K31/519, A61K31/5377, A61K31/554, A61P31/12, A61K31/7064, A61K31/712, A61P31/20, A61K31/522, A61K31/675, A61K31/683, A61K47/54 | [2022/44] | CPC: |
C12N15/1131 (EP);
A61K31/519 (EP,US);
A61K31/4375 (EP);
A61K31/506 (EP);
A61K31/554 (EP);
A61K31/675 (EP);
A61K31/7064 (EP);
A61K31/713 (EP);
A61K47/549 (EP);
A61K48/005 (US);
A61P31/20 (US);
C12N2310/11 (EP);
| C-Set: |
A61K31/4375, A61K2300/00 (EP);
A61K31/506, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP);
A61K31/554, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K31/7064, A61K2300/00 (EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/44] | Title | German: | PHARMAZEUTISCHE KOMBINATION EINES THERAPEUTISCHEN OLIGONUCLEOTIDS GEGEN HBV UND EINES TLR7-AGONISTEN ZUR BEHANDLUNG VON HBV | [2022/44] | English: | PHARMACEUTICAL COMBINATION OF A THERAPEUTIC OLIGONUCLEOTIDE TARGETING HBV AND A TLR7 AGONIST FOR TREATMENT OF HBV | [2022/44] | French: | ASSOCIATION PHARMACEUTIQUE D'UN OLIGONUCLÉOTIDE THÉRAPEUTIQUE CIBLANT LE VHB ET UN AGONISTE DE TLR7 POUR LE TRAITEMENT DU VHB | [2022/44] | Entry into regional phase | 14.07.2022 | National basic fee paid | 14.07.2022 | Designation fee(s) paid | 14.07.2022 | Examination fee paid | Examination procedure | 14.07.2022 | Examination requested [2022/44] | 14.07.2022 | Date on which the examining division has become responsible | 07.02.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 09.12.2022 | Renewal fee patent year 03 | 19.12.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XI]WO2014032176 (REPLICOR INC [CA]) [X] 125,128,129,136,137,140,142,143,150,151 * examples 3, 4; claims 1, 2, 11-17, 51, 60-67, 93-98 * * the whole document * [I] 92,95-153; | [YD]WO2014179627 (ISIS PHARMACEUTICALS INC [US]) [YD] 1,70 * example 113; table 108 * * the whole document *; | [AD]WO2015132276 (HOFFMANN LA ROCHE [CH], et al) [AD] 1-158* the whole document *; | [XDYI]WO2015173208 (HOFFMANN LA ROCHE [CH], et al) [XD] 125,129,136,137,140,143,150,151 * page 103, lines 8-11; claims 1-21 * * the whole document * [Y] 1,47-69,77,78 [I] 92,95-153; | [XDI]WO2016077321 (ALNYLAM PHARMACEUTICALS INC [US]) [XD] 125,128,129,136,137,140,142,143,150,151 * page 150, line 25 - page 151, line 2; claims 85, 143, 145 * * the whole document * [I] 92,95-153; | [AD]WO2016091698 (HOFFMANN LA ROCHE [CH], et al) [AD] 1-158 * the whole document * * page 30, lines 8-9; example 47 *; | [Y]WO2016146598 (HOFFMANN LA ROCHE [CH], et al) [Y] 87-90 * table 1 * * figure 4 * * example 7 * * page 24, paragraph 1 * * page 25, lines 8-11 * * the whole document *; | [IY]WO2017211791 (HOFFMANN LA ROCHE [CH], et al) [I] 1,2,71-74,79-86,91-158 * claims 1, 6, 8, 34; tables 1, 6; compounds 7-14 * * the whole document * [Y] 1-70,75-78,87-90; | [Y]WO2019079781 (DICERNA PHARMACEUTICALS INC [US]) [Y] 1-46,75,76 * figure 10; claims 13, 47 * * the whole document *; | [IY] - BLAISING JULIE ET AL, "Combination treatment of liver-targeted hbv locked nucleic acid antisense oligonucleotide and tlr7 agonist ro7020531 leads to prolonged off-treatment antiviral effect in the aav-hbv mouse model", HEPATOLOGY,, (20190930), vol. 70, no. Suppl. 1, ISSN 0270-9139, pages 428A - 429A, XP009519336 [I] 92,95-153 * the whole document * [Y] 1,47-70,77,78 | [Y] - HASSAN JAVANBAKHT ET AL, "Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo", MOLECULAR THERAPY: NUCLEIC ACIDS., US, (20180223), vol. 11, doi:10.1016/j.omtn.2018.02.005, ISSN 2162-2531, pages 441 - 454, XP055675496 [Y] 1,47-69,77,78 * figure 2A * * the whole document * DOI: http://dx.doi.org/10.1016/j.omtn.2018.02.005 | by applicant | WO9839352 | US5885968 | WO9914226 | WO0047599 | WO0066604 | WO0123613 | WO2004046160 | WO2004083430 | WO2006066080 | WO2007085485 | WO2007090071 | WO2007107162 | US2007254362 | WO2007134181 | WO2007146511 | WO2008049085 | WO2008113832 | US2008274462 | WO2008150729 | WO2008154401 | WO2009006478 | US2009099115 | WO2009067647 | WO2010033225 | WO2010036698 | WO2010077578 | WO2011017521 | WO2011133871 | US2011294869 | WO2011156202 | WO2012109395 | US8372968 | US8513207 | WO2013154798 | WO2014076195 | WO2014076196 | WO2014088920 | EP2742135 | WO2014179627 | WO2014179620 | US8883996 | WO2014207232 | US8927513 | US8927705 | US9012138 | US9012621 | WO2015132276 | WO2015173208 | US9193753 | WO2015188197 | WO2016055553 | WO2016055601 | WO2016077321 | WO2016091698 | WO2016100401 | WO2017178656 | WO2018098328 | - SORIANO et al., Expert Opinion on Investigational Drugs, (20170000), vol. 26, page 843 | - CHEONG et al., Nature, (19900816), vol. 346, no. 6285, pages 680 - 2 | - HEUSPARDI, Science, (19910712), vol. 253, no. 5016, pages 191 - 4 | - CORNISH-BOWDEN, Nucl. Acids Res., (19850000), vol. 13, pages 3021 - 3030 | - WOESE et al., Proc Natl Acad Sci USA., (19901100), vol. 87, no. 21, pages 8467 - 71 | - ANTAO et al., Nucleic Acids Res., (19911111), vol. 19, no. 21, pages 5901 - 5 | - NAKANO et al., Biochemistry, (20020000), vol. 41, no. 48, pages 14281 - 14292 | - SHINJI et al., Nippon Kagakkai Koen Yokoshu, (20000000), vol. 78, no. 2, page 731 | - HIRAO et al., Accounts of Chemical Research, (20120000), vol. 45, page 2055 | - MERGNYLACROIX, Oligonucleotides, (20030000), vol. 13, pages 515 - 537 | - HANSEN et al., Chem. Comm., (19650000), pages 36 - 38 | - SANTALUCIA, Proc Natl Acad Sci USA., (19980000), vol. 95, pages 1460 - 1465 | - SUGIMOTO et al., Biochemistry, (19950000), vol. 34, pages 11211 - 11216 | - MCTIGUE et al., Biochemistry, (20040000), vol. 43, pages 5388 - 5405 | - HUCH et al., Nature, (20130000), vol. 494, no. 7436, pages 247 - 250 | - FREIERALTMANN, Nucl. Acid Res., (19970000), vol. 25, pages 4429 - 4443 | - UHLMANN, Curr. Opinion in Drug Development, (20000000), vol. 3, no. 2, pages 293 - 213 | - DELEAVEYDAMHA, Chemistry and Biology, (20120000), vol. 19, page 937 | - MORITA et al., Bioorganic & Med. Chem. Lett., vol. 12, pages 73 - 76 | - SETH et al., J. Org. Chem., (20100000), vol. 75, no. 5, pages 1569 - 81 | - MITSUOKA et al., Nucleic Acids Research, (20090000), vol. 37, no. 4, pages 1225 - 1238 | - WANSETH, J. Medical Chemistry, (20160000), vol. 59, pages 9645 - 9667 | - PRAKASH et al., Nucleic Acids Res., (20150000), vol. 43, no. 6, pages 2993 - 3011 | - CHANG, Semin Fetal Neonatal Med, (20070000), vol. 12, pages 160 - 167 | - BASTIN, Organic Process Research & Development, (20000000), vol. 4, pages 427 - 435 | - BIESSEN et al., J. Med. Chem., (19950000), vol. 39, pages 196,1456 - 1546 | - "Prodrugs and Drug Delivery Systems", RICHARD B. SILVERMAN, Organic Chemistry of Drug Design and Drug Action, Academic Press, (20040000), pages 497 - 558 | - KRAYNACKBAKER, RNA, (20060000), vol. 12, pages 163 - 176 | - MOORE et al., Methods Mol. Biol., (20100000), vol. 629, pages 141 - 158 | - SUN et al., Nat. Biotechnol., (20080000), vol. 26, pages 1379 - 1382 | - CHANG et al., Mol Ther, (20090400), vol. 17, no. 4, pages 725 - 32 | - HOHJOH, FEBS Letters, (20040100), vol. 557, pages 193 - 198 | - ELSNER, Nature Biotechnology, (20120000), vol. 30, page 1063 | - ABE et al., J Am Chem Soc, (20070000), vol. 129, pages 15108 - 15109 | - BRAMSEN et al., Nucleic Acids Res., (20090000), vol. 37, no. 17, pages 2867 - 2881 | - HAMILTON et al., Embo J., (20020000), vol. 21, no. 17, pages 4671 - 4679 | - MATSUI et al., Molecular Therapy, (20160500), vol. 24, no. 5, pages 946 - 955 | - BRAMSENKJEMS, Frontiers in Genetics, (20120000), vol. 3, pages 1 - 22 | - KOSHKIN et al., Tetrahedron, (19980000), vol. 54, pages 3607 - 3630 | - SNEAD et al., Molecular Therapy - Nucleic, (20130000), page e103 | - IMANISHIOBIKA, Chem. Commun., The Royal Society of Chemistry, (20020000), pages 1653 - 1659 | - PRAKASH et al., Nucleic Acids Res., Nucleic Acids Res., (20150331), vol. 43, no. 6, pages 2993 - 3011 | - VAN AERSCHOT et al., "An acyclic 5-nitroindazole nucleoside analogue as ambiguous nucleoside", Nucleic Acids Res., (19951111), vol. 23, no. 21, doi:10.1093/nar/23.21.4363, pages 4363 - 70, XP001537631 DOI: http://dx.doi.org/10.1093/nar/23.21.4363 | - LOAKES et al., "3-Nitropyrrole and 5-nitroindole as universal bases in primers for DNA sequencing and PCR", Nucleic Acids Res., (19950711), vol. 23, no. 13, pages 2361 - 6, XP002109690 | - LOAKESBROWN, "5-Nitroindole as an universal base analogue", Nucleic Acids Res., (19941011), vol. 22, no. 20, pages 4039 - 43, XP000999195 | - MEADE et al., Nature Biotechnology, (20140000), vol. 32, pages 1256 - 1263 | - DELLINGER et al., J. Am. Chem. Soc., (20030000), vol. 125, pages 940 - 950 | - KHOREV et al., Bioorg. Med. Chem., (20080000), vol. 16, page 5216 | - DUFF et al., Methods Enzymol, (20000000), vol. 313, page 297 | - BIESSEN et al., Cardovasc. Med., (19990000), page 214 | - DAN YANG et al., Cellular & Molecular Immunology, (20140000), vol. 11, pages 71 - 78 | - GUO et al., Sci Rep, (20160000), vol. 6, page 2552 | - YAN et al., J Hepatology, (20170000), vol. 66, no. 6, pages 1149 - 1157 | - KAKUNI et al., Int. J. Mol. Sci., (20140000), vol. 15, pages 58 - 74 | - "GenBank", Database accession no. AM282986.1 | US19500604326 | US19510604326 | WO2018EP78136 |